10-KPeriod: FY2001

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2001

Filed April 1, 2002For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated, in its 2001 10-K filing, highlights its progress as a biotechnology company focused on discovering, developing, and commercializing novel small molecule drugs. The company has one marketed product, Agenerase (amprenavir), an HIV protease inhibitor, with worldwide sales of $71.9 million in 2001, generating $10.8 million in royalties for Vertex. Vertex boasts a robust pipeline with over 12 additional drug candidates in various stages of clinical and preclinical development, targeting significant unmet medical needs in infectious diseases, inflammation, autoimmune diseases, cancer, neurological disorders, and genetic disorders. The company's core strength lies in its proprietary chemogenomics platform and gene family-based drug design strategy, aimed at increasing the efficiency and productivity of drug discovery. Significant collaborations with major pharmaceutical companies like GlaxoSmithKline, Novartis, Aventis, and Eli Lilly provide substantial financial support and resources. The acquisition of Aurora Biosciences in July 2001 further strengthened Vertex's drug discovery platform by integrating Aurora's assay development and screening capabilities. Despite significant investments in research and development and continued operating losses, Vertex expresses confidence in its ability to commercialize multiple products in the coming years and generate increased revenue streams.

Key Highlights

  • 1Vertex has one marketed product, Agenerase (amprenavir) for HIV, generating $10.8 million in royalties in 2001 from $71.9 million in global sales.
  • 2The company has a diverse pipeline with over 12 drug candidates in clinical and preclinical development across key therapeutic areas including infectious diseases, inflammation, autoimmune diseases, cancer, and neurological disorders.
  • 3Vertex utilizes a proprietary chemogenomics platform and gene family-based drug design strategy to accelerate drug discovery.
  • 4Significant collaborations with major pharmaceutical companies (e.g., GlaxoSmithKline, Novartis, Aventis, Eli Lilly) provide substantial funding and development/commercialization resources.
  • 5The acquisition of Aurora Biosciences in July 2001 enhanced Vertex's drug discovery capabilities with advanced assay development and screening technologies.
  • 6Vertex is actively pursuing new drug candidates, with several programs targeting kinases, caspases, proteases, and ion channels, and has new research programs in bacterial gyrase and genetic disorders.
  • 7The company incurred a net loss of $66.2 million for the year ended December 31, 2001, but maintained substantial cash reserves of $743.2 million.

Frequently Asked Questions

Vertex's primary revenue streams are derived from royalties on Agenerase sales, product sales (primarily from Aurora's business), services (assay development, screening), and collaborative research and development agreements. In 2001, total revenues were $167.5 million, with collaborative R&D contributing $69.0 million, product sales $59.9 million, services $27.5 million, and royalties $11.1 million.

Vertex is focusing on discovering and developing drugs for significant unmet medical needs across several key therapeutic areas: infectious diseases (HIV, Hepatitis C), inflammation and autoimmune diseases (rheumatoid arthritis, psoriasis), cancer, neurological disorders (Alzheimer's, Parkinson's), and genetic disorders.

Vertex funds its R&D through a combination of sources, including milestone payments and research funding from its numerous collaborations with large pharmaceutical companies, royalty revenue from Agenerase, product sales, services provided by Aurora, existing cash reserves, and potential future financing.

The acquisition of Aurora Biosciences in July 2001 significantly strengthened Vertex's drug discovery platform by integrating Aurora's advanced assay development, screening technologies, and cell biology capabilities. This merger created a more comprehensive and scalable platform expected to accelerate the output of drug candidates.